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Background: The purpose of the present study was to assess the vision-related quality of life 
(QOL) of visually impaired patients using the Japanese 11-item National Eye Institute Visual 
Function Questionnaire (VFQ-J11). Comparisons with the 25-item version (VFQ-25) and the 
EuroQoL Index using a large group of patients with various degrees of impairments and various 
causative diseases were performed.
Methods: A total of 232 visually impaired Japanese patients were recruited from six ophthal-
mology departments in Japan. Information on ophthalmic findings and patient backgrounds was 
collected, and information on QOL and utility assessments was collected from the patients by 
means of survey questionnaires.
Results: The average age of patients was 69.6±14.3 years. Both the vision-related QOL 
scores (VFQ-25 composite and VFQ-J11) were significantly associated with better and worse 
visual acuity (VA) in visually impaired subjects (all P,0.01). VFQ-J11 was comparable to 
VFQ-25 regardless of causative diseases. VFQ-25 composite and the VFQ-J11 scores were 
concurrently associated with a range of systemic medical disorders. EuroQoL Index had a 
significant association with better eye VA (P,0.01), but not with worse eye VA, or any sys-
temic disorders.
Conclusion: VFQ-J11 provides valid data on vision-related QOL and is less of a burden for 
patients with vision problems.
Keywords: quality of life, utility, visual acuity, visual impairment, VFQ-25, EQ-5D
Introduction
Normal vision is an important element of health and quality of life (QOL).1 Blindness 
and visual impairments are among the ten most common causes of disability in the US 
and are associated with both a shorter life expectancy and a lower QOL.2,3 Moreover, 
the visually impaired elderly have an increased risk of falls and fractures,4–6 as well 
as depression.7,8 In addition, individuals with impaired vision are at an increased risk 
of traffic accidents9,10 and are more likely to cease or curtail their driving.11 Thus, 
individuals with visual impairments may suffer from functional and psychosocial 
burdens in various aspects of their daily lives.
The importance of evaluating the burden of disease on QOL from a patient-
centered standpoint is widely recognized. For quantitative evaluation of patient-
reported outcomes, it is essential to apply measurement tools with verified reliability 
and validity. The National Eye Institute Visual Function Questionnaire (VFQ) was 
developed to assess the QOL of individuals with visual impairments. It originally 
comprised 51 items and was later shortened to 25 items and 13 optional items that 
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generated subscales.12 The 25-item version (VFQ-25) has 
been validated in many countries, including Japan,13 and is 
widely used as a standard questionnaire for a wide variety 
of targeted populations, such as the elderly and those with 
visual impairments.14
Although the VFQ-25 is a shorter version of the original 
VFQ, it still contains 25 essential items and 13 optional 
items.12,13 For patients in a clinical setting, responding to 
many questions about visual function, sometimes via an 
interviewer, can impose a substantial burden. The Japanese 
11-item National Eye Institute Visual Function Questionnaire 
(VFQ-J11) was recently developed as a shortened version 
of the VFQ-25 by using the item response theory.15,16 This 
11-item questionnaire is expected to be easy to use and less 
time-consuming, while maintaining good psychometric 
properties. The purpose of the present study was to assess 
the vision-related QOL of visually impaired patients using 
the VFQ-J11 and the VFQ-25. Comparison of these mea-
sures using a large group of patients with various degrees of 
impairments and various causative diseases was performed to 
determine whether the VFQ-J11 was capable of capturing the 
vision-related QOL. In addition, we investigated health utility 
by using the EuroQoL Index (EQ-5D) measure, which is com-
monly used for the assessment of generic health utility.17,18
Participants and methods
Participants
This study was part of a nested study entitled “The Health 
Economics Research on Vision Screening for Adults”, 
funded by the Ministry of Health, Labour and Welfare of 
Japan. Data were collected from a multicenter survey con-
ducted between September 2011 and December 2012. A total 
of 232 visually impaired Japanese patients were recruited 
from the following six ophthalmology departments in Japan: 
The National Hospital Organization Tokyo Medical Center, 
Keio University School of Medicine, Juntendo University 
Main Hospital, Juntendo Tokyo Koto Geriatric Medical 
Center, Jikei University, and Kyoto University.
Inclusion criteria were as follows: adult patients (age $20 
years) who had ocular conditions that resulted in visual 
impairments, best-corrected visual acuity (VA) #0.6 in at 
least one eye. The inclusion criteria were set according to 
the visual impairment classification in the Japanese Welfare 
of Physically Disabled Persons Act. Any disease resulting 
in visual impairment was acceptable, but limited to chronic 
and invariable conditions. Patients who had the possibility 
of improvement through medical or surgical intervention 
were therefore excluded. Patients who had severe systemic 
diseases, dementia, psychological diseases, or severe 
functional impairments such as immobility or limb defects 
were also excluded. Patients with treatable systemic diseases, 
such as hypertension, diabetes mellitus, and stroke, were 
included.
This study protocol was approved by the Institu-
tional Review Board of each clinical site, including Keio 
University, Tokyo Medical Center, Juntendo University 
Main Hospital, Juntendo Tokyo Koto Geriatric Medical 
Center, Jikei University, and Kyoto University. This study 
was conducted in accordance with the tenets of the Declara-
tion of Helsinki, and the Ethical Guidelines for Medical and 
Health Research Involving Human Subjects in Japan. The 
patients received a full explanation of the procedures and 
provided their written informed consent for participation 
prior to inclusion in the study.
Methods
For the 232 patients, information on ophthalmic findings was 
collected from the responsible physicians. QOL and utility 
assessment was performed by means of self-reported survey 
questionnaires. The questionnaires consisted of the Japanese 
versions of EQ-5D tool and VFQ-25, including the optional 
questions.13,18 The reliability and validity of the Japanese 
versions of the EQ-5D and VFQ-25 are considered to be 
comparable to the English versions.13,18 The VFQ-J11 score 
was calculated from the VFQ-25 by including responses to 
the optional questions.15
Decimal VA was examined at a distance of 5 m. Decimal 
VA values of ,0.01 were expressed by the following: 
counting fingers was categorized as an acuity of 0.004, hand 
motion as 0.002, light perception as 0.001, and no light per-
ception as 0.0005.19,20 For simple linear regression analysis, 
decimal VA values were converted to the logarithm of the 
minimum angle of resolution (logMAR).
The causative eye diseases of visual impairment were 
classified as corneal disease, lens disease, glaucoma, diabetic 
retinopathy, macular degeneration, degenerative myopia, 
retinitis pigmentosa, amblyopia, optic nerve atrophy, and 
others. We selected the top six diseases (n.10) for further 
analyses.
The VFQ-25 consisted of 25 questions and 13 optional 
items organized into 12 subscales (one assessing general 
health and the remainder targeting vision-specific functions) 
ranging from 0 to 100.12 The composite score and the average 
score across the eleven subscales related to vision-specific 
functions were a useful summary of visual function. Lower 
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Vision-related QOl assessment in visually impaired patients using VFQ-J11
2, 5, 6, 8, 11, 17, 24, 25, and optional items 3, 6, and 8 of 
the VFQ-25.15 We calculated the VFQ-J11 score from the 
VFQ-25 by including responses to the optional questions.15
The EQ-5D is one of the standard methods for assess-
ing the utility value. The EQ-5D is a multi-attribute utility 
classification system for preferences associated with generic 
health states.17,18 The EQ-5D consists of five questions on 
mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Each item is scored on a 3-point scale 
(none/moderate/extreme) according to the severity of the 
problem. Individual sets of answers were converted to the 
utility value. The EQ-5D provides a single index value for 
clinical and economical evaluation of health care, frequently 
used for cost–effectiveness analysis.
statistical analysis
The associations between various factors and QOL char-
acteristics, including VFQ-25, VFQ-J11, and EQ-5D, 
were assessed using single linear regression models. Asso-
ciation estimates (beta coefficients) from these models were 
expressed as the mean difference in grade per unit of change 
in each factor. All P-values were two-tailed. All statistical 
analyses were performed using SPSS statistical software for 
Windows, version 21 (IBM Corporation, Armonk, NY, USA). 
A value of P,0.05 was set as the threshold of significance.
Results
Demographic data are summarized in Table 1. The age of 
the participants (n=232) enrolled in the study ranged from 
20 to 93 years (average, 69.6±14.3 years) and 123 of the 
participants were male (54.9%). The average VA in logMAR 
units was 0.48±0.64 in the better eye and 1.58±1.04 in the 
worse eye (Table 1). The main causes of visual impairment 
were age-related macular degeneration (53 patients), dia-
betic retinopathy (34), glaucoma (33), corneal diseases (21), 
retinitis pigmentosa (14), and degenerative myopia (11). 
Others (47) included various disorders, such as retinal vein 
occlusion, retinal artery occlusion, angioid streaks, uveitis, 
chorioretinal atrophy, macular dystrophy, and phthisis of 
unknown etiology. A summary of QOL scores is shown in 
Table 2. The mean VFQ-J11 scores and VFQ-25 composite 
scores were 49.0±24.8 and 51.8±23.8, respectively, while 
the mean EQ-5D utility was 0.74±0.19.
We investigated possible associations between QOL 
parameters and various demographic factors using simple 
linear regression analysis (Table 3). High scores of VFQ-25 
composite, VFQ-J11, and EQ-5D were significantly associ-
ated with VA in the better eye (VFQ-25, P,0.01; VFQ-J11, 
P,0.001; EQ-5D, P,0.01, respectively). For VFQ-25 and 
VFQ-J11, low scores were significantly associated with VA 
in the worse eye (VFQ-25, P,0.01; VFQ-J11, P,0.01, 
respectively). QOL scores were not associated with sex or 
age. The VFQ-25 composite and the VFQ-J11 scores were 
significantly associated with systemic comorbidities, such as 
hypertension, diabetes mellitus, digestive disorders, neuro-
logical disorders, and hearing loss. However, EQ-5D had no 
significant association with any systemic conditions.
We next investigated the relationships between QOL 
scores and the better/worse eye VA in detail. The results are 
summarized in Table 4. When the better eye VA was .0.6, 
scores of both measures of vision-related QOL (VFQ-J11 and 
VFQ-25) were independent of the worse eye VA (analysis 
of variance [ANOVA], P.0.05). However, when the better 
eye VA was #0.6, the vision-related QOL scores of patients 
decreased with the worse eye VA (ANOVA, P,0.05), sug-
gesting that the QOL scores were mainly associated with VA 
in the better eye, but not with the worse eye.
Table 1 Patient demographics (n=232)
Mean ± SD, n, or n (%) Range or n
sex (% male) 123 (54.9%)
age (years) 69.6±14.3 20–93

















Optic disc atrophy 5
Others 47
Abbreviations: arMD, age-related macular degeneration; BCVa, best-corrected 
visual acuity; logMar, logarithm of the minimum angle of resolution; nlP, no light 
perception; sD, standard deviation.
Table 2 summary of quality of life scores




VFQ-J11 49.0±24.8 49.3 (26.9–69.1) 2.3–100 0–100
VFQ-25 51.8±23.8 53.5 (33.4–71.1) 0–95.2 0–100
eQ-5D 0.74±0.19 0.73 (0.61–1.00) −0.014–1.00 −0.6–1.0
Note: higher values indicate better health for the VFQ-25.
Abbreviations: eQ-5D, euroQol index; iQr, interquartile range; sD, 
standard deviation; VFQ-J11, Japanese 11-item national eye institute Visual 
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Table 3 associations between quality of life parameters and various demographic factors
Parameters VFQ-25 composite score VFQ-J11 score EQ-5D score
Slope (95% CI) P-value Slope (95% CI) P-value Slope (95% CI) P-value
age −0.12 (−0.34, 0.10) 0.27 −0.17 (−0.40, 0.06) 0.15 0.000 (−0.002, 0.001) 0.77
sex −5.6 (−11.8, 0.59) 0.08 −3.84 (−10.4, 2.79) 0.26 0.028 (−0.022, 0.077) 0.27
Visual acuity
Better-eye BCVa (logMar) −20.3 (−24.4, −16.2) ,0.01 −25.9 (−29.7, −22.1) ,0.01 −0.108 (−0.144, −0.073) ,0.001
Worse-eye BCVa (logMar) −6.95 (−9.80, −4.11) ,0.01 −6.06 (−9.13, −2.99) ,0.01 −0.018 (−0.041, 0.005) 0.12
systemic comorbidities
hypertension −6.64 (−13.1, −0.22) 0.04 −6.69 (−13.6, −0.17) 0.04 −0.037 (−0.087, 0.014) 0.16
angina 5.79 (−7.58, 19.2) 0.39 4.36 (−9.60, 18.3) 0.54 0.026 (−0.079, 0.13) 0.62
Diabetes mellitus −7.12 (−13.9, −0.38) 0.04 −7.86 (−14.9, −0.74) 0.03 −0.036 (−0.089, 0.017) 0.18
Cancer 4.90 (−13.1, 22.9) 0.59 2.62 (−16.1, 21.4) 0.78 −0.10 (−0.24, 0.038) 0.15
Kidney disorder −9.07 (−23.5, 5.38) 0.22 −7.49 (−23.3, 8.30) 0.35 −0.048 (−0.16, 0.066) 0.41
Digestive disorder −28.8 (−52.1, −5.43) 0.02 −31.2 (−59.3, −3.14) 0.03 −0.087 (−0.27, 0.010) 0.36
respiratory disorder −11.9 (−39.1, 15.3) 0.39 −13.9 (−42.3, 14.3) 0.33 −0.094 (−0.31, 0.12) 0.38
neurological disorder −52.1 (−98.6, −5.65) 0.03 −51.1 (−99.6, 2.57) 0.04 0.11 (−0.15, 0.36) 0.42
stroke −4.21 (−22.2, 13.8) 0.65 0.62 (−19.6, 20.8) 0.95 −0.021 (−0.16, 0.12) 0.77
hearing loss −27.3 (−48.2, −6.41) 0.01 −26.1 (−50.5, −1.67) 0.04 −0.163 (−0.33, 0.002) 0.053
Abbreviations: BCVA, best-corrected visual acuity; CI, confidence interval; EQ-5D, EuroQoL Index; logMAR, logarithm of the minimum angle of resolution; VFQ-25, 25-
item national eye institute Visual Function Questionnaire; VFQ-J11, Japanese 11-item national eye institute Visual Function Questionnaire.
Table 4 Quality of life parameters based upon the BCVa of the 
better/worse eye






0.6, 75 15 8






0.6, 66.4±20.5 68.2±15.1 70.5±18.0






0.6, 68.0±15.9 65.1±17.8 71.2±15.2






0.6, 0.82±0.18 0.82±0.15 0.88±0.14
Note: Data presented as number of subjects or mean ± standard deviation.
Abbreviations: BCVa, best-corrected visual acuity; eQ-5D, euroQol index; 
sD, standard deviation; VFQ-25, 25-item national eye institute Visual Function 
Questionnaire; VFQ-J11, Japanese 11-item national eye institute Visual Function 
Questionnaire.
We also examined QOL parameters by causative disease 
(Table 5). Although patients with glaucoma had the lowest 
VFQ-J11 score and VFQ-25 composite score compared 
with the other ocular diseases, they were not statistically 
significant (ANOVA, P.0.05). Vision-related QOL scores 
(VFQ-J11 and composite VFQ-25) were mainly dependent 
on VA levels in the better eye for all causative diseases. The 
utility value determined by EQ-5D showed a low variation 
for VA groups regardless of causative diseases (ANOVA, 
P.0.05).
Discussion
We have assessed QOL and the utility of visually impaired 
subjects with various backgrounds by means of survey 
questionnaires consisting of the EQ-5D, VFQ-25, and 
VFQ-J11. Both VFQ-25 composite scores and VFQ-J11 
scores were significantly associated with the better eye VA 
and worse eye VA. However, EQ-5D scores showed a sig-
nificant association with the VA of the better eye, but not 
the worse eye. The VFQ-25 composite and VFQ-J11 scores 
were concurrently associated with a range of systemic disor-
ders among the visually impaired subjects, while the EQ-5D 
scores were not associated with any systemic disorders. Our 
results are consistent with previous studies that reported that 
EQ-5D is not sensitive enough to assess the impact of the 
severity of ocular diseases on the QOL.21,22
We then examined the possible relationships between 
QOL and the better/worse eye VA. Our results confirmed 
that the VA of the better eye predominantly affected the 
QOL of visually impaired individuals.23 Both vision-related 
QOL measures (VFQ-25 and VFQ-J11) indicated that their 
scores were independent of the worse eye VA, when the 
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Vision-related QOl assessment in visually impaired patients using VFQ-J11
was #0.6, their scores decreased with the worse eye VA.24 
Our data also showed that the decline in QOL scores was 
present even with unilateral modest visual impairment, with 
no threshold effect in VFQ-25 and VFQ-J11.25
We also investigated the relationship between QOL 
parameters and causative eye diseases and found that 
causative diseases affected vision-related QOL to a limited 
degree. Generally, vision-related QOL scores correlated 
with the better eye VA for all causative diseases. Although 
statistically not significant, vision-related QOL scores for 
glaucoma patients were low, even among individuals with the 
same VA level. This may be because glaucoma patients have 
greater visual field defects than do other visually impaired 
participants.26 We also found that VFQ-J11 and VFQ-25 
scores varied more widely than EQ-5D scores, suggesting 
that the VFQ-J11 and VFQ-25 are equally useful for evaluat-
ing QOL in severely visually impaired patients, regardless 
of the causative disease.
This study has some limitations. Although we intended 
to enroll various visually impaired patients from six oph-
thalmology departments, the causative diseases of visual 
impairments might not be a representative sampling of the 
Japanese population. We calculated the VFQ-J11 from the 
completed VFQ-25 in the study to avoid repetition. The VFQ-
J11 scores might be different if the VFQ-J11 was completed 
as a standalone instrument. In addition, we did not determine 
the associations between the QOL scores and visual field 
defects. For this purpose, visual function indices such as the 
Functional Vision Score, which includes visual field evalua-
tion, should, in the future, be compared with QOL scores.27
Conclusion
In summary, we found that both VFQ-25 composite and 
VFQ-J11 scores were significantly associated with the better 
eye and worse eye VA in visually impaired patients, and that 
they were sensitive enough to evaluate the QOL in visually 
impaired patients, regardless of the causative diseases. These 
results suggested that the VFQ-J11 and VFQ-25 are equally 
useful indicators of vision-related QOL. Considering that 
VFQ-J11 is less than half as long as the VFQ-25, the VFQ-
J11 provides valid data for vision-related QOL, while being 
less of a burden for patients.
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Total 21 14 34 33 53 11
BCVa group #0.3 8 2 19 14 12 6
0.4–0.6a 5 6 11 6 11 2
0.6, 8 6 4 13 30 3
VFQ-J11 score
(mean ± sD)
Total 57.8±25.3 50.7±21.4 40.3±23.6 36.4±25.7 55.1±23.3 45.9±23.6
BCVa group #0.3 40.0±23.9 32.8±9.6 31.7±22.2 16.9±16.7 23.2±11.8 28.1±11.9
0.4–0.6a 57.8±26.2 40.7±19.7 44.6±18.0 40.4±21.4 53.4±18.7 56.6±8.0




Total 49.1±31.8 52.8±17.9 44.4±21.2 41.8±24.8 58.6±22.8 54.7±21.9
BCVa group #0.3 35.4±29.3 40.3±18.6 37.0±20.2 27.7±17.2 34.9±12.3 38.7±13.7
0.4–0.6a 46.0±32.9 45.7±14.9 48.9±17.0 39.1±24.8 54.5±24.9 64.9±6.1
0.6, 64.6±30.4 64.2±16.3 67.2±20.3 58.2±23.1 69.7±17.1 80.1±8.4
eQ-5D score
(mean ± sD)
Total 0.71±0.18 0.74±0.18 0.66±0.15 0.71±0.18 0.81±0.18 0.76±0.17
BCVa group #0.3 0.70±0.16 0.60±0.02 0.63±0.17 0.63±0.18 0.70±0.22 0.66±0.09
0.4–0.6a 0.72±0.17 0.64±0.14 0.68±0.09 0.68±0.06 0.79±0.19 0.79±0.29
0.6, 0.70±0.23 0.89±0.12 0.78±0.15 0.81±0.16 0.86±0.14 0.93±0.12
Notes: VA group classified using the better eye best-corrected visual acuity BCVA (decimal). aData shown as range.
Abbreviations: BCVa, best-corrected visual acuity; eQ-5D, euroQol index; QOl, quality of life; VFQ-J11, Japanese 11-item national eye institute Visual Function 
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